Q-omics provides the consensus-scored RORA-AS2 profile across patient tissues and cancer cell-line models. RORA-AS2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RORA-AS2 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RORA-AS2 RNA expression shows 14,032 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight DLBC, THCA, and CCRCC as cancer lineages where RORA-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RORA-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RORA-AS2 survival associations across molecular data types. RORA-AS2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RORA-AS2 RNA expression–survival associations across cancer types. High RORA-AS2 expression shows unfavorable associations in DLBC, UVM, THYM and LUSC, but favorable associations in HNSC and BRCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RORA-AS2 RNA expression.
This table summarizes RORA-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RORA-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RORA-AS2 shows lower tumor expression in THCA and LIHC and higher tumor expression in LIHC. The THCA box plot shows higher RORA-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p = .001).
This table shows molecular features associated with RORA-AS2 in patient tissues and cancer cell lines. In patient samples, RORA-AS2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
